CV Sciences Inc. (OTCMKTS:CVSI) has announced
that it plans to submit a Request of Continued Examination of its 15/426,617
patent application with the US Patent Trademark Office. The patent is titled
Pharmaceutical Formulations Containing Cannabidiol and Nicotine For Treating
Smokeless Tobacco Addiction.
Filing for an RCE
The intention to file for a Request of Continued Examination comes after the USPTO notified CV Sciences that the Patent Trial and Appeal Board declined their appeal to reverse the decision of the examiner to deny specific claims that were made in the company’s patent application.
The Chief Executive Officer of CV Sciences, Joseph Dowling, stated that the decision of USPTO was disappointing. It was important to note that it was not the end of the process. He added that the company plans to make the request continued examination. He said that they are confident in the protection of the company’s intellectual property regarding the formulation as well as the ability of CV Sciences to commercialize the invention.
that they believe the innovation will offer a solution to the persistent
epidemic in smokeless tobacco addiction. He added that the company would remain
focused on the development of proprietary products that can enhance the quality
of life of its customers.
PlusCBD Oil leading product in the CBD market
CV Sciences runs
two different business segments which are consumer product divisions and the
drug development division. The consumer division focuses on manufacturing,
selling, and marketing of their CBD products to different markets. The drug
development segment focuses on the development and commercialization of
innovative CBD-based therapeutics, that utilize CBD.
The company’s PlusCBD oil is top-selling hemp-derived CBD product, and according to the CEO, consumers choose the product because of its quality, purity, and consistency. Dowling indicates that the company offers a premium product line of gluten-free and non-GMO full spectrum CBD products in the market. CV Science’s full-spectrum hemp extracts are produced, tested, and processed in the company’s state of the art facility, to ensure products conform to its standards.
Pellicer Worldwide Inc (OTCMKTS:DPWW) has announced signing a Letter of
Intent to acquire Denver…
Brands Inc. (OTCMKTS:VATE)
has announced a rollout of its latest hemp-infused single-serve coffee…
MediPharm Labs Corp (OTCMKTS:MEDIF) entered a contract manufacturing deal for packaging and filling…
Inc (OTCMKTS:PURA) has
given a pat on the back of Aurora
Cannabis Inc (NYSE:ACB) for its decision…
Published at Wed, 25 Sep 2019 12:10:01 +0000